LIMD1 and lung adenocarcinoma: To further confirm whether the p38 MAPK signaling pathway is involved in the LIMD1-mediated increase in the sensitivity of lung adenocarcinoma cells to cisplatin, we either treated cells with SB203580 or transfected siRNA into cells to inhibit p38 MAPK signaling pathway activity.